Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model

Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical modelEradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model, Published online: 12 February 2019; doi:10.1038/s41388-019-0737-2Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model

Source: Oncogene - February 12, 2019 Category: Cancer & Oncology Authors: Francesco Alessandrini Laura Menotti Elisa Avitabile Irene Appolloni Davide Ceresa Daniela Marubbi Gabriella Campadelli-Fiume Paolo Malatesta Source Type: research